These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16583343)

  • 21. A new therapeutic monoclonal antibody.
    Freeman PR
    J Am Pharm Assoc (Wash); 1996 Feb; NS36(2):90-1. PubMed ID: 8742006
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness and safety of abciximab after failed thrombolytic therapy.
    Cantor WJ; Kaplan AL; Velianou JL; Sketch MH; Barsness GW; Berger PB; Ohman EM
    Am J Cardiol; 2001 Feb; 87(4):439-42, A4. PubMed ID: 11179529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double vessel occlusions after balloon angioplasty treated by stenting and subsequently by abciximab infusion.
    Bertrand OF; Meerkin D; de Guise P; Crépeau J; Bourassa MG
    Can J Cardiol; 2000 Jan; 16(1):83-5. PubMed ID: 10653937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the use of abciximab in percutaneous coronary intervention.
    Iversen AZ
    Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
    [No Abstract]   [Full Text] [Related]  

  • 27. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Profound thrombocytopenia after abciximab administration in acute myocardial infarction and stent thrombosis following thrombocytopenia remission--a case report].
    Elikowski W; Rzeźniczak J; Słomczyński M; Psuja P
    Kardiol Pol; 2005 Jan; 62(1):44-7; discussion 48. PubMed ID: 15815778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Constrictive pericarditis after inferoposterior myocardial infarction].
    Gómez-Barrado JJ; Vega J; Turégano S; Marcos G
    Med Intensiva; 2006 Oct; 30(7):343-4. PubMed ID: 17067509
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
    Parodi G; Sciagrà R; Migliorini A; Memisha G; Moschi G; Valenti R; Pupi A; Antoniucci D
    Am Heart J; 2005 Aug; 150(2):220. PubMed ID: 16086921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 32. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.
    Vahdat B; Canavy I; Fourcade L; Garcia E; Quilici J; Bonnet JL; Bory M
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):177-80. PubMed ID: 10642768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
    Zijlstra F
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):222-3. PubMed ID: 19156883
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary artery stenting in MI and Abciximab: a necessary combination?
    Block PC
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):180. PubMed ID: 9377647
    [No Abstract]   [Full Text] [Related]  

  • 37. Free wall rupture following rescue angioplasty and intravenous abciximab for failed thrombolysis.
    Balachandran KP; Oldroyd KG
    Scott Med J; 2001 Jun; 46(3):87-8. PubMed ID: 11501328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
    Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
    Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.
    Khanlou H; Tsiodras S; Eiger G; Abousy K; Goldberg S; Nakhjavan F; Yazdanfar S
    Cathet Cardiovasc Diagn; 1998 Jul; 44(3):313-6. PubMed ID: 9676804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The FINESSE trial].
    Petronio AS; Piscione F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):1-5. PubMed ID: 19292014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.